Skip to main content
Clinical Trials/NCT00795249
NCT00795249CompletedPhase 1

Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle

Kurume University1 site in 1 country100 target enrollmentStarted: November 1, 2008Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
100
Locations
1
Primary Endpoint
The number of circulating EMP

Study Overview

Brief Summary

The investigators hypothesized that circulating EMP is a useful surrogate marker of early stage of endothelial damage. To determine the effects of chronic smoking on circulating EMP, from healthy volunteers who have habit of chronic smoking, peripheral blood is drawn at the time of flow-mediated dilatation (FMD) examination. Spot urine is also collected. Circulating EMPs are counted using flow-cytometry. After 2-week smoking cessation, the measurements were repeated.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
20 Years to 40 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •healthy individuals who have no coronary risk factors

Exclusion Criteria

  • •hypertension
  • •dyslipidemia
  • •chronic kidney disease
  • •liver dysfunction
  • •obesity (BMI>25.0)
  • •cerebrovascular disease
  • •other severe systemic diseases (cancer, inflammatory diseases, etc)

Arms & Interventions

non-smoker

No Intervention

the age-matched healthy volunteers

smoker

Experimental

Individuals who have a habit of chronic smoking without any coronary risk factors

Intervention: smoking cessation (Behavioral)

Outcomes

Primary Outcomes

The number of circulating EMP

Time Frame: 2 weeks

Secondary Outcomes

  • FMD(2 weeks)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials